Bailard Inc. lowered its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 3.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 77,257 shares of the conglomerate's stock after selling 2,538 shares during the quarter. Bailard Inc.'s holdings in Danaher were worth $15,838,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors also recently added to or reduced their stakes in DHR. Mayflower Financial Advisors LLC boosted its holdings in Danaher by 12.3% in the first quarter. Mayflower Financial Advisors LLC now owns 2,846 shares of the conglomerate's stock worth $583,000 after acquiring an additional 312 shares in the last quarter. Jacobson & Schmitt Advisors LLC boosted its holdings in Danaher by 3.5% in the first quarter. Jacobson & Schmitt Advisors LLC now owns 92,106 shares of the conglomerate's stock worth $18,882,000 after acquiring an additional 3,115 shares in the last quarter. Lineweaver Wealth Advisors LLC boosted its holdings in Danaher by 19.3% in the first quarter. Lineweaver Wealth Advisors LLC now owns 3,764 shares of the conglomerate's stock worth $772,000 after acquiring an additional 608 shares in the last quarter. Allen Capital Group LLC lifted its holdings in shares of Danaher by 38.7% during the first quarter. Allen Capital Group LLC now owns 2,059 shares of the conglomerate's stock worth $422,000 after purchasing an additional 574 shares during the period. Finally, Welch & Forbes LLC lifted its holdings in shares of Danaher by 0.8% during the first quarter. Welch & Forbes LLC now owns 690,602 shares of the conglomerate's stock worth $141,573,000 after purchasing an additional 5,749 shares during the period. Institutional investors own 79.05% of the company's stock.
Danaher Stock Down 2.5%
DHR traded down $4.81 on Friday, reaching $189.98. The company's stock had a trading volume of 4,239,169 shares, compared to its average volume of 3,523,488. The stock has a market cap of $135.96 billion, a price-to-earnings ratio of 36.89, a price-to-earnings-growth ratio of 2.67 and a beta of 0.77. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. The business's 50 day moving average is $196.13 and its 200 day moving average is $205.03.
Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. As a group, research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.
Danaher Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.67%. Danaher's payout ratio is currently 24.85%.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on DHR. TD Cowen boosted their price target on Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a report on Wednesday, April 23rd. Leerink Partners increased their price target on Danaher from $225.00 to $230.00 and gave the stock an "outperform" rating in a report on Wednesday, April 23rd. The Goldman Sachs Group decreased their price objective on Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Evercore ISI cut their target price on Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Finally, HSBC cut their price target on Danaher from $270.00 to $240.00 in a research report on Friday, April 25th. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $248.48.
Get Our Latest Report on Danaher
Insider Activity at Danaher
In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president owned 15,179 shares in the company, valued at $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman owned 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.10% of the company's stock.
About Danaher
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
